DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Comment by TrueNorth911on Nov 30, 2018 4:20pm

77 Views

Post# 29047464

RE:Lest we Forget

Encouraging post!

I can't stop thinking of where DMA could go as we run up to release of trial results. Look at RETA. Their market cap went from $900M to $2.5B based on readouts! And that's based on a subset of CKD only!...

I only ask one simple question.... how the heck did they even get to $900M market cap?.... If that were DMA's valuation, we'd be holding a golden ticket at $90/share! after on NASDAQ!. So I must think the only real difference is that RETA is listed on the NASDAQ and they do have insitutional following/support with decent brokerage/underwriting support.

So...isn't that what your eluding to POENTIALLY happening shortly??? I'm excited to say the least!

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading